Sundar PichaiSundar Pichai earned $164M in 2023
X

Simon N. Pimstone

Founder and Ex-CEO of Xenon Pharmaceuticals

Education

MBChB from the University of Cape Town; FRCPC from the University of British Columbia; Ph.D. from the University of Amsterdam in cardiovascular genetics

Field of Expertise

Healthcare & Life Sciences - Medicine

Born

January 1, 1967 - 58 years ago

Economy Sector

Healthcare

Tenure

18 years 0 months (Jan 2003 - Jan 2021)

Previous Experience

Consultant Physician at the University of British Columbia Hospital, Cardiology Clinic; Clinical Associate Professor at the University of British Columbia, Division of General Internal Medicine; Investigator at the Centre for Heart Lung Innovation; Chair of the board of Eupraxia Pharmaceuticals Inc., TopiRx Pharmaceuticals, and Alpha9 Theranostics Inc.

Simon N. Pimstone is the former CEO of Xenon Pharmaceuticals, where he led the company from 2003 until 2021. With a diverse background in medicine and research, he holds an MBChB from the University of Cape Town, a Ph.D. in...

Year

2021

Total Compensation

$1.01M

Salary

$525.00K

Board Justification

The primary objectives of our Compensation Committee with respect to executive compensation are to attract, retain and motivate experienced and talented executives; ensure executive compensation is aligned with our corporate strategies, research and development programs and business goals; recognize the individual contributions of executives, but foster a shared commitment among executives by aligning their individual goals with our corporate objectives; promote the achievement of key strategic and operational performance measures by linking compensation to the achievement of measurable corporate and individual performance goals; and align the interests of our executives with our shareholders by rewarding performance that leads to the creation of shareholder value.

Bonus

$450.39K

Board Justification

The annual cash bonus is based on the achievement of corporate objectives that focus on specific research, clinical, regulatory, operational and financial milestones, with a focus on the advancement of our product candidates in preclinical and clinical development, the pursuit of various internal initiatives and ensuring the adequate funding of the Corporation. The corporate objectives are proposed by the Chief Executive Officer, the NEOs and other members of senior management each year in our annual operating plan that is reviewed and approved, following consultation with the Board, by our Compensation Committee, with such modifications as the Compensation Committee deems appropriate. The Compensation Committee determined that the majority of Clinical goals were met and that the Pre-Clinical Research and Business/Financial Operations goals were exceeded, resulting in an aggregate achievement of 150% for corporate objectives in 2021.

Other

$35.60K

Board Justification

Other compensation includes life insurance premiums, other insurance premiums, and contributions intended for retirement savings.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock grants are mentioned as vested in 2021 for Simon N. Pimstone.

Performance Metrics

The performance metrics for the CEO that determine the compensation in 2021 are based on the achievement of specified annual corporate objectives, including clinical trial milestones and operational goals.